Fig. 5

Enforced expression of DAB2 predisposes mice to a serially transplantable myeloid malignancy. a Schematic of the primary transplant experiment analyzed in b through g. CBC complete blood counts, LDA limiting dilution assay. b A Kaplan–Meier survival curve was generated for mice receiving transplanted marrow containing Vector or DAB2 constructs following primary (1° DAB2) or secondary transplant (2° DAB2) in those mice dying of myeloproliferation or leukemia. c Peripheral blood analysis of white blood cells (WBCs), platelets (Plt), mean cell volume (MCV), and hemoglobin (HGB) at 25 weeks post transplant (mean ± SEM, Vector n = 9, 1° DAB2 n = 16, 1° DAB2-AML/MPD n = 7, 2° DAB2 n = 8). d Spleen weights were assessed in primary and secondary recipients (mean ± SEM, Vector n = 6, 1° DAB2-AML/MPD n = 6, 2° DAB2-AML/MPD n = 8). e CFU analysis was performed using primary DAB2-AML/MPD marrow sorted for GFP (mean ± SEM, GFP- BM n = 3, GFP + BM n = 4). f Frequency of LSK (Lin⁻Sca1⁺c-Kit⁺), CMP (Lin⁻Sca1⁻c-Kit⁺CD34⁺CD16/32^lo), GMP (Lin⁻Sca1⁻c-Kit⁺CD34⁺CD16/32^hi) and MEP (Lin⁻Sca1⁻c-Kit⁺CD34⁻CD16/32^lo) determined by flow cytometry in GFP⁺ marrow of 1° DAB2 mice 60 weeks post transplant that did not develop leukemia or a myeloproliferative disorder (mean ± SEM, Vector n = 3–5, 1° DAB2 n = 3–4). g Secondary limiting dilution assays using marrow from long-term engrafted Vector or DAB2 mice (52 weeks post-primary transplant). Engraftment was evaluated in secondary recipients at 16 weeks post transplant. Shown is a log-fraction plot of the limiting dilution model. The slope of the line is the log-active cell fraction. The dotted lines give the 95% CI